Clinical Trials Browser

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03618550 2025-12-02

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Recruiting

257 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT04875195 2025-10-29

MK-3475-B68

Phase 2 Completed

66 enrolled 16 charts

Lymphoid

Hodgkin Disease

NCT05922904 2025-10-10

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Phase 2 Active not recruiting

25 enrolled

Lymphoid

Hodgkin Disease

NCT06812858 2025-08-19

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

Phase 2 Recruiting

83 enrolled

Lymphoid

Hodgkin Disease

NCT03331341 2025-08-05

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Phase 1/2 Completed

50 enrolled 10 charts

Lymphoid

Hodgkin Disease

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

17 enrolled

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT03179917 2025-05-07

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Phase 2 Active not recruiting

22 enrolled

Lymphoid

Hodgkin Disease

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Phase 2 Recruiting

71 enrolled

Lymphoid

Hodgkin Disease

NCT04134325 2025-04-16

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Phase EARLY_PHASE1 Active not recruiting

10 enrolled

Lymphoid

Hodgkin Disease

NCT06045195 2025-04-06

Pembro-FLASH

Phase 2 Not yet recruiting

40 enrolled

Lymphoid

Hodgkin Disease

NCT04788043 2025-04-02

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Phase 2 Active not recruiting

8 enrolled

Lymphoid

Hodgkin Disease

Clinical Trials

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

MK-3475-667

MK-3475-204

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

MK-4280-003

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

KEYNOTE145

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

MK-3475-B68

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Pembro-FLASH

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma